Slide 1: Gilead to Acquire Kite: Creating a Global Leader in Cell Therapy
Gilead to Acquire Kite: Creating a Global Leader in Cell Therapy August 28, 2017
Slide 2: Disclaimer and Forward-Looking Statements
Disclaimer and Forward-Looking Statements This presentation includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are stateme
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It The tender offer described in this document has not yet commenced. This announcement is neither an offer to purchase nor a solicitation of an offer to sell shares of Kite. A solicitation and an offer to buy shares of Kite will be made only pursuant to an o
Slide 4: Gilead + Kite: Bringing Life-Saving Therapies to Patients
Gilead + Kite: Bringing Life-Saving Therapies to Patients • Kite’s platform, pipeline and scientific expertise establish Gilead’s leadership in cell therapy for oncology • Builds a foundation for dramatically improving treatment of hematological malignancies and solid tumors • Gilead has transformed
Slide 5: Transaction Details
Transaction Details • Gilead to acquire Kite for $180 per share in cash or total purchase price of $11.9 billion ̶ Transaction is expected to be neutral to earnings by year three and accretive thereafter ̶ The acquisition represents a 29 percent premium to Kite’s closing on Friday, August 25, and a
Slide 6: Kite: An Overview
Kite: An Overview • Kite is headquartered in Santa Monica, California and has ~650 employees, with operations in the U.S., Europe and joint venture in China (FosunKite) • Axi-cel, the company’s lead product, is under review with a U.S. PDUFA date of Nov. 29, 2017 and European approval anticipated in
Slide 7: Ready to Launch
Ready to Launch • Kite has fully-integrated infrastructure to launch first-in-class, best-in-class treatment for three types of aggressive non-Hodgkin lymphoma, with other indications to follow • Kite has a state-of-the-art, commercial scale cell therapy processing facility, located in El Segundo (L
Slide 8: Understanding Cell Therapy
Understanding Cell Therapy 8
Slide 9: Cell Therapy: An Emerging Field with the Potential to Transform Cancer Treatment
Cell Therapy: An Emerging Field with the Potential to Transform Cancer Treatment • Cell therapy is a new way of treating cancer that uses a patient’s own immune system to fight the disease • Kite’s industry-leading cell therapy pipeline is based on two different platforms: CAR (chimeric antigen rece
Slide 10: The Science of CAR T
The Science of CAR T CAR T How it Works • T cells are taken from patients and engineered to express chimeric antigen receptors (CARs), which direct T cells to detect and destroy tumor cells • Upon engagement with the specified cancer cell, the CAR T-cell “activates” resulting in the killing of the t
Slide 11: Exciting Data Published Across Numerous Journals
Exciting Data Published Across Numerous Journals “These results show that anti-CD19 CAR T- cells can cause long complete responses of chemotherapy-refractory DLBCL and that Kochenderfer, James N. et al. Molecular Therapy, 13 July 2017 (online pub.) anti-CD19 CAR T cells are possibly a curative thera
Slide 12: Axi-Cel is Nearing Approval in First Indication
Axi-Cel is Nearing Approval in First Indication Axicabtagene Ciloleucel (axi-cel): • Under priority FDA review for aggressive non-Hodgkin lymphoma which includes diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (TFL) and primary mediastinal B-cell lymphoma (PMBCL) • Under revie
Slide 13: Lack of Therapeutic Options for People with DLBCL
Lack of Therapeutic Options for People with DLBCL • Diffuse large B-cell lymphoma is the most common form of non-Hodgkin lymphoma • Outcomes for patients with DLBCL whose disease has relapsed or who have become refractory to existing therapies are poor (SCHOLAR-1 study): ̵ Initial complete response
Slide 14: Axi-Cel Pivotal Data Illustrate Promise of CAR T
Axi-Cel Pivotal Data Illustrate Promise of CAR T • Results from Kite’s ZUMA-1 pivotal trial in which patients with relapsed/ refractory DLBCL were treated with axi-cel: ̵ Initial complete response treated with axi-cel: 54 percent ̵ Median overall survival: Not yet reached at 8.7 months 54% Complete
Slide 15: Kite Has a Comprehensive Pipeline
Kite Has a Comprehensive Pipeline 15
Slide 16: Kite: Ongoing Launch Preparation
Kite: Ongoing Launch Preparation 16
Slide 17: Reaching DLBCL Patients
Reaching DLBCL Patients Cumulative percentage of total DLBCL patients covered by transplant centers 1 year 70+ 70+ centers % of patients 9 months targeted by end of 6 months year 1, reaching ~90% 3 months of people with Launch DLBCL # of transplant centers 17
Slide 18: A Patient-Centered Approach
A Patient-Centered Approach • Kite Konnect™ program will create optimal experience for patients and physicians • Field teams fully staffed and trained • Company has diligently worked to prepare first sites to treat patients and anticipates launching with at least 10 leading cancer centers Vein to ve
Slide 19: European Union: Preparing to Launch in 2018
European Union: Preparing to Launch in 2018 • Axi-cel EU submission completed in July 2017 • Building infrastructure – leadership with proven oncology track record • Enrolling patients in clinical sites • Building network with thought leaders and clinical organizations • Establishing supply chain 19
Slide 20: Gilead: A History of Innovation
Gilead: A History of Innovation 20
Slide 21: Gilead Has Transformed Care for People with HIV
Gilead Has Transformed Care for People with HIV HAART 1996 2006 B/F/TAF PDUFA 2/12/2018 6 STRs over a 12-year period 21
Slide 22: Gilead Has Transformed Care for People with HCV
Gilead Has Transformed Care for People with HCV 4 options to cure HCV in 4 years 22
Slide 23: Together, We Will…
Together, We Will… • Drive continuous scientific and medical innovation to improve care for people with cancer • Develop next generations of novel therapies in areas of significant unmet need • Design and execute clinical programs to shorten development timelines • Scale complicated manufacturing pr
Slide 24: Gilead to Acquire Kite: Creating a Global Leader in Cell Therapy
Gilead to Acquire Kite: Creating a Global Leader in Cell Therapy August 28, 2017